Physician profile
Andrea Dunn
NPI 1013476951
$4,151.16
in general payments reported to CMS, 2019-2025
20 companies · $1,584 in 2025
The $1,584 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $311 · 2023: $768 · 2024: $1,488 · 2025: $1,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,840.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,365.53 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $536.28 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $489.07 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $343.69 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $235.67 | 2022-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $206.77 | 2025 | Auvelity, Symbravo |
| Dexcom, INC. | $184.43 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Astellas Pharma US INC | $172.47 | 2024-2025 | Veozah |
| Pfizer INC. | $152.22 | 2023-2025 | |
| Exact Sciences Corporation | $135.17 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $103.74 | 2024-2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $52.87 | 2022-2024 | Quviviq |
| Philips North America LLC | $31.11 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Abbott Laboratories | $24.12 | 2025 | Freestyle Libre 3 |
| Lundbeck LLC | $24.00 | 2025 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $22.81 | 2025 | Vibativ |
| Bayer Healthcare Pharmaceuticals INC. | $20.15 | 2025 | |
| Merck Sharp & Dohme LLC | $19.05 | 2025 | M-M-R II, Capvaxive, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $17.24 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $14.77 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.